home / stock / otlkw / otlkw quote
Last: | $0.03 |
---|---|
Change Percent: | -1.96% |
Open: | $0.02 |
Close: | $0.03 |
High: | $0.035 |
Low: | $0.01 |
Volume: | 156,240 |
Last Trade Date Time: | 02/16/2022 04:55:25 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.03 | $0.02 | $0.03 | $0.035 | $0.01 | 156,240 | 02-16-2022 |
$0.0306 | $0.04 | $0.0306 | $0.04 | $0.02 | 122,537 | 02-15-2022 |
$0.041 | $0.05 | $0.041 | $0.05 | $0.025 | 18,641 | 02-14-2022 |
$0.0499 | $0.0798 | $0.0499 | $0.096 | $0.02 | 78,034 | 02-11-2022 |
$0.076 | $0.04 | $0.076 | $0.0797 | $0.0351 | 181,066 | 02-10-2022 |
$0.0341 | $0.0356 | $0.0341 | $0.0378 | $0.034 | 29,212 | 02-09-2022 |
$0.0356 | $0.029 | $0.0356 | $0.0356 | $0.0125 | 3,151 | 02-08-2022 |
$0.0369 | $0.039 | $0.0369 | $0.039 | $0.029 | 12,311 | 02-07-2022 |
$0.0394 | $0.03 | $0.0394 | $0.0394 | $0.0297 | 7,399 | 02-04-2022 |
$0.029 | $0.0303 | $0.029 | $0.0305 | $0.029 | 11,304 | 02-03-2022 |
$0.0405 | $0.0302 | $0.0405 | $0.0416 | $0.0302 | 4,238 | 02-02-2022 |
$0.0416 | $0.0304 | $0.0416 | $0.0416 | $0.0304 | 26,501 | 02-01-2022 |
$0.0425 | $0.0425 | $0.0425 | $0.0425 | $0.04 | 34,160 | 01-31-2022 |
$0.0293 | $0.049899 | $0.0293 | $0.0499 | $0.0293 | 3,925 | 01-28-2022 |
$0.0499 | $0.049 | $0.0499 | $0.05 | $0.0425 | 13,422 | 01-26-2022 |
$0.0348 | $0.044 | $0.0348 | $0.0473 | $0.0348 | 30,091 | 01-25-2022 |
$0.049 | $0.0488 | $0.049 | $0.049 | $0.0488 | 3,111 | 01-24-2022 |
$0.0441 | $0.0448 | $0.0441 | $0.0499 | $0.0415 | 76,750 | 01-21-2022 |
$0.045 | $0.0412 | $0.045 | $0.0454 | $0.0412 | 32,973 | 01-20-2022 |
$0.0412 | $0.04 | $0.0412 | $0.0425 | $0.021 | 29,932 | 01-19-2022 |
News, Short Squeeze, Breakout and More Instantly...
Outlook Therapeutics Inc. Series A Warrant Company Name:
OTLKW Stock Symbol:
NASDAQ Market:
Outlook Therapeutics Inc. Series A Warrant Website:
Live video webcast on Tuesday, June 18 th at 12:00 PM ET ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; be...
LYTENAVA™ (bevacizumab gamma) becomes first ophthalmic formulation of bevacizumab to receive European Commission Marketing Authorization for the treatment of wet AMD European Commission decision applies automatically to all 27 EU Member States and, within 30 days, also to Iceland, ...
Positive opinion received from Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for ONS-5010/LYTENAVA™ (bevacizumab gamma) United Kingdom (UK) Marketing Authorization Application (MAA) submitted NORSE EIGHT fully underway in the U...